{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04648254",
            "orgStudyIdInfo": {
                "id": "Q702-ONC-P1-US001"
            },
            "organization": {
                "fullName": "Qurient Co., Ltd.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor",
            "officialTitle": "A Phase 1, Multicenter, Open-label, Dose- Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 With a Cohort Expansion at the RP2D in Patients With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "oral-axl-mer-selective-tyrosine-kinase-inhibitor-in-patients-with-advanced-solid-tumor"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2020-11-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-11-19",
            "studyFirstSubmitQcDate": "2020-11-23",
            "studyFirstPostDateStruct": {
                "date": "2020-12-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-02",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Qurient Co., Ltd.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor",
                "Advanced Cancer",
                "Metastatic Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 78,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose escalation (Q702)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive escalating doses of Q702",
                    "interventionNames": [
                        "Drug: Q702"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Q702",
                    "description": "The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.",
                    "armGroupLabels": [
                        "Dose escalation (Q702)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the safety profile of Q702",
                    "timeFrame": "28 days of cycle 1"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in the area under curve (AUC) of Q702",
                    "timeFrame": "Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22"
                },
                {
                    "measure": "Change in the maximum plasma concentration (Cmax) of Q702",
                    "timeFrame": "Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22"
                },
                {
                    "measure": "Change in the time of maximum plasma concentration (Tmax) of Q702",
                    "timeFrame": "Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22"
                },
                {
                    "measure": "Tumor response using RECIST version 1.1 throughout study",
                    "timeFrame": "Baseline up to approximately 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically or cytologically confirmed advanced or metastatic solid tumors, that have progressed following standard of care therapy or for which there is no standard therapy which confers clinical benefit\n* Measurable disease per RECIST v 1.1\n* ECOG performance status 0 or 1\n* Life expectancy of at least 3 months\n* Age \u2265 18 years\n* Signed, written IRB-approved informed consent form\n\nExclusion Criteria:\n\n* New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months\n* Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of \\>470 msec (females) and \\>450 msec (males)\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy\n* Active, poorly controlled autoimmune or inflammatory diseases",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Qurient Clinical Trial Information",
                    "role": "CONTACT",
                    "phone": "+82-31-8060-1610",
                    "phoneExt": "(KST)",
                    "email": "clinicaltrial_info@qurient.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Southern California",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "See Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Cedars-Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "See Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Northwestern University",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "See Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Atlantic Health System Hospital",
                    "status": "RECRUITING",
                    "city": "Morristown",
                    "state": "New Jersey",
                    "zip": "07960",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "See Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.79677,
                        "lon": -74.48154
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Metastatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2889",
                    "name": "Tyrosine Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}